

In re application of:

Avi ASHKENAZI, et al.

Application Serial No. 10/633,008

Filed: July 31, 2003

Examiner: Unassigned

Art Unit: 1641

Attorney's Docket No. 39766-0100 P1

Customer No. 25213

For: USE OF A33 ANTIGENS AND JAM-IT

EXPRESS MAIL LABEL NO. <u>EL 977 676 755 US</u>

Date Mailed: FEBRUARY 20, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Missing Parts

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

| ⊠ apply): | This st | tatemen | It qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that |
|-------------------------------|--|--------------------|---|
| | | (1) | It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR |
| | | (2) | It is being filed within 3 months of entry of a national stage |
| | \boxtimes | (3) | It is being filed before the mail date of the first Office Action on the merits OR |
| | | (4) | It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. |
| | 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then: | | |
| | | a certif | ication as specified in §1.97(e) is provided below; or |
| | | | f \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or d with the payment of other papers filed together with this statement. |
| | 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then: | | |
| | A. | a certif | ication as specified in §1.97(e) is completed below; and |
| | B. | | on under 37 C.F.R. §1.97(d) requesting consideration of this statement is ted herewith; and |
| | C. | a fee o include | f \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or d with the payment of other papers filed together with this statement. |
| | Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39766-0100 P1)</u> . | | |
| | | - | Respectfully submitted, |
| Dated: | Februa | ary 20, 2 | |
| 275 Mid Menlo I Telepho | ddlefield Park, C one: (6 | d Road | -7000 |

-2-

Sheet 1 of Attorney's Docket No. Application Serial No. 39766-0100 P1 10/633.008 INFORMATION DISCLOSURE STATEMENT Applicant(s) Avi ASHKENAZI, et al. Filing Date: **Group Art Unit:** (use several sheets if necessary) July 31, 2003 1641 U.S. PATENT DOCUMENTS Examiner Ref. Date Document No. Name Filing Date Class **Subclass** Initials No. (if appropriate) 1. 04/01/86 4.579.827 Sakamoto et al. 436 536 FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Name Class Subclass **Translation** Initials No. YES NO 2. 10/29/86 0 199 141 C07K 15/00 Europe 3. 09/28/94 0 616 812 A1 Europe A61K 39/395 09/28/94 0 616 812 B1 Europe 39/395 A61K OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Title **Examiner** Ref. Initials No. 5. Boyum, A. "A One Stage Procedure for Isolation of Granulocytes and Lymphocytes from Human Blood," Norweigan Defense Establishment, Div. Of Toxicology, pp. 51-76 Martin-Padura, I. et al, "Junctional Adhesion Molecule, aNovel Member of the Immunoglobulin Superfamily That 6. Distributes at Intercellular Junctions and Modulates Monocyte Transmigration," J. Cell Biol. 142 (1): 117-27 (1998) Monks, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cel 7. Lines," Natl. Cancer Inst. 83: 757-766 (1991) Skehan. P. et al., "New Colorimetric Cytoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82: 1107-8. Spencer, S. et al., "The Orphan Receptor CRF2-4 is an Essential Subunit of the Interleukin 10 Recepto," J. Exp. Med. 9. 187: 571-578 (1998). 10. Taylor, S. et al., "The Human Homologue of Bub3 Is Required for Kinetochore Localization of Bub1 and a Mad3/Bub1-Related Protein Kinase," J. Cell. Biol. 142 (1): 1-11 (1998) 11. Welt, S. et al., "Quantative Analysis of Antibody Localization in Human Metastatic Colon Cancer: A Phase I Study of Monoclonal Antibody A33," J. Clin. Oncol. 8: 1894-1906 (1990) 12. Welt, S. et al., "Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon Cancer," J. Clin. Oncol. 12: 1561-1571 (1994)

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2009086 v2